Saad Usmani, MD, MBA, FACP, FASCO

Articles

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Guidance and Future Plans

October 21st 2024

In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Prophylactic Measures

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss the need for continued evaluation of prophylactic treatments like tocilizumab and antimicrobial measures for bispecific T-cell engagers.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Management Strategies

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Awareness of AEs

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique AEs like CRS and the need for well-defined protocols.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Overview

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique toxicities.

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

October 14th 2024

Dr. Saad Usmani discusses the results of the Phase 3 CEPHEUS study, which evaluated the combination of daratumumab with bortezomib/lenalidomide/dexamethasone (D-VRd) in transplant-ineligible or transplant-deferred patients with newly diagnosed multiple myeloma, highlighting its impact on progression-free survival and minimal residual disease negativity.

Dr Usmani on Challenges With Bispecifics and CAR T-Cell Therapies in Multiple Myeloma

October 3rd 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses challenges of integrating bispecific antibodies and CAR T-cell therapies into the community for myeloma.

Dr Usmani on the Efficacy of Daratumumab Plus VRd in Newly Diagnosed, Transplant-Ineligible Myeloma

October 1st 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the efficacy of daratumumab plus VRd in patients with transplant-ineligible or -deferred multiple myeloma.

FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

April 22nd 2024

Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.

Dr Usmani on the Risk-Benefit Profile of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 15th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the risk-benefit profile of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr Usmani on the Optimal Role for Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 10th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the optimal role for ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr Usmani on the FDA Approval of Cilta-Cel for Relapsed/Refractory Multiple Myeloma

April 6th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the FDA approval of cilta-cel for relapsed/refractory multiple myeloma.

Treatment Considerations and Sequencing in Multiple Myeloma

February 19th 2024

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

February 19th 2024

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

GPRC5D-Targeting Bispecifics in Multiple Myeloma

February 12th 2024

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.

Adverse Effects Related to Bispecifics in Multiple Myeloma

February 12th 2024

Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.

Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

February 5th 2024

Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.

Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

February 5th 2024

Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.

Updates on BCMA-Targeting Bispecifics in MM

January 29th 2024

An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.

Potential Role for CAR T-Cell Therapy in MM at Early Relapse

January 29th 2024

Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.